Accessibility Menu
Harrow logo

Harrow(NASDAQ) HROW

Market Cap$1.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+352%
5 Year+275%
1 Year+4%
1 Month-0%
Premium Feature
Moneyball Superscore
69/100
$38.50
-1.41%
-0.55Today
Harrow last closing stock price
MetricPriceDate
Last closeUSD 39.052026-09-02
Harrow stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.71%USD 39.332026-08-26
1 month-0.1%USD 39.092026-08-03
3 month+12.57%USD 34.692026-06-04
Year to date-20.31%USD 49.002025-12-31
1 year+3.53%USD 37.722025-09-02
3 year+152.1%USD 15.492023-09-01
5 year+274.76%USD 10.422021-09-03
Since inception+351.52%USD 8.652007-04-24

Harrow Financials at a Glance

Market Cap

$1.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$275.59M

Net Income (TTM)

-$37.23M

EPS (TTM)

-$1.00

P/E Ratio

-39.07

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$38.50

Volume

207,233.633

Open

$39.12

Previous Close

$39.05

Daily Range

$38.13 - $39.33

52-Week Range

$28.54 - $54.85

Estimated Earnings Date

Nov 9, 2026

HROW News

SellAlert-Green.png

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Andy GouldMar 24, 2026
BuyAlert-Red.png

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%

Jonathan PoncianoNov 27, 2025
optometrist covering her patient’s eyes with an occluder during an eye exam

Why Shares of Harrow Health Are Jumping Wednesday

James HalleyJul 19, 2023
ophthalmologist eye doctor examines patient

Why Shares of Harrow Health Are Slumping Friday

James HalleyMay 12, 2023

HROW: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harrow

Harrow, Inc. makes medicines that help people improve their eyesight. It sells prescription eye drugs to doctors and patients. The company also mixes custom medications for specific eye needs.

Focusing on Eye Care

  • Dry Eye Treatments: Medicines like VEVYE and TYRVAYA that address symptoms of chronic dry eye disease.
  • Custom Compounded Formulations: Specialized medications mixed by the ImprimisRx business to meet specific patient or physician needs.
  • Branded Ophthalmic Products: Portfolio of prescription drugs including IHEEZO and TRIESENCE for various ocular conditions.
  • Nasal Spray Solutions: TYRVAYA nasal spray 0.03%, a treatment for dry eye signs and symptoms acquired in Aug. 2026.

How the Company Grows

  • Acquired the global rights to TYRVAYA nasal spray from Viatris in Aug. 2026 for $30 million upfront.
  • Issued $50 million in senior notes in March 2026 to fund operations and potential future acquisitions.
  • Expanded the research pipeline by integrating a drug candidate from Melt Pharmaceuticals in Nov. 2025.
  • Refinanced long-term debt and established a $40 million revolving line of credit in Sept. 2025.

What Makes Harrow Stand Out

Harrow maintains one of the largest portfolios of branded ophthalmic pharmaceutical products in North America. By operating its own pharmaceutical compounding business, the company provides a comprehensive range of customized and standardized solutions for eye care professionals.

A Look at the Numbers

  • Total net revenues reached $114.9 million for the six-month period ended June 30, 2026.
  • Branded revenue rose to $86.8 million during the first half of 2026, compared to $70.1 million in 2025.
  • Compounding revenue was $28.1 million for the six months ended June 30, 2026.
  • The company reported $83.9 million in cash and cash equivalents as of June 30, 2026.
  • Market capitalization was $1.6 billion in Q2 2026, up 41.2% year over year.

Bottom Line

Harrow has evolved from a compounding-focused business into a diversified pharmaceutical firm with a growing portfolio of branded eye care products. Its recent acquisitions and debt financing strategy reflect a focused effort to expand its footprint in the North American ophthalmic market.

AI Generated • Aug 11, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

373

CEO

Mark L. Baum

Website

www.harrow.com

Headquarters

Nashville, TN 37215, US

HROW Financials

Key Financial Metrics (TTM)

Gross Margin

73.28%

Operating Margin

2.07%

Net Income Margin

-13.51%

Return on Equity

-103.86%

Return on Capital

12.68%

Return on Assets

-8.93%

Earnings Yield

-2.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.49M

Volume

207.23K

Avg. Volume

649.74K

Financials (TTM)

Gross Profit

$201.96M

Operating Income

$5.70M

EBITDA

$4.48M

Operating Cash Flow

$6.25M

Capital Expenditure

-$566.00K

Free Cash Flow

$5.69M

Cash & ST Invst.

$83.89M

Total Debt

$300.74M

Harrow Performance Analysis

Harrow annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 88,595,00022.2%
20232023-12-31USD 130,193,00047.0%
20242024-12-31USD 199,614,00053.3%
20252025-12-31USD 272,303,00036.4%
Harrow sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3012.4%
Q42025-12-3124.4%
Q12026-03-31-50.4%
Q22026-06-3059.9%
Harrow annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.51-25.7%
20232023-12-31USD -0.7545.9%
20242024-12-31USD -0.49-34.5%
20252025-12-31USD -0.14-71.5%
Harrow sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-79.8%
Q42025-12-31587.0%
Q12026-03-31-511.1%
Q22026-06-3037.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$70.66M

+10.9%

Gross Profit

$50.36M

+6.0%

Gross Margin

71.27%

N/A

Market Cap

$1.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.92M

N/A

Employees

373

N/A

Net Income

-$17.27M

-445.7%

EBITDA

-$11.01M

-168.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$83.89M

+50.3%

Total Debt

$300.74M

+30.1%

Accounts Receivable

$118.56M

+50.4%

Inventory

$16.91M

+46.4%

Long Term Debt

$299.80M

+539.9%

Short Term Debt

$944.00K

-99.5%

Return on Assets

-8.93%

N/A

Return on Invested Capital

1.81%

N/A

Free Cash Flow

-$9.56M

-886.7%

Operating Cash Flow

-$9.76M

-1114.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KMTSKestra Medical Technologies, Ltd.
$25.42-1.19%
BLFSBioLife Solutions, Inc.
$35.25-1.88%
ALVOAlvotech
$5.36+0.28%
DVAXDynavax Technologies Corporation
$15.50+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.69+0.14%
SPCXSpace Exploration Technologies
$151.43+0.08%
NVDANvidia
$227.39+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.91+0.05%

Questions About HROW

What is the current price of Harrow?

Harrow is trading at $38.44 per share.

What is the 52-week range for Harrow?

Over the past 52 weeks, Harrow has traded between $28.54 and $54.85.

How much debt does Harrow have?

As of the most recent reporting period, Harrow reported total debt of $300.74M.

How much cash does Harrow have on hand?

Harrow reported $83.89M in cash and cash equivalents in its most recent financial results.

What is Harrow’s dividend yield?

Harrow does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services